The role
Job description
About the company In the near future, drug discovery will no longer be the bottleneck in life sciences: Eli Lilly's $2B+ partnership with Insilico Medicine, Anthropic's $400M+ acquisition of Coefficient Bio, and OpenAI's partnership with Novo Nordisk. Capital and resources are flowing into drug discovery, but this doesn't address the downstream bottleneck — if there is an abundance of molecules discovered, how eligible are they for regulatory approval and commercialization? Deffai is reimagining
Index terms